AstraZeneca is a lagging far behind Novo Nordisk and Eli Lilly in the obesity treatment field, but is determined to succeed with next-generation treatments and combinations that go beyond short-term weight loss.
The company unveiled early-stage data for its trio of key assets on 4 November at the Obesity Week congress in...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?